System for achieving high-specificity killing of targeted cells and method thereof using magneto-electric nano-particles

Patent metadata

Field	Value
Publication number	US-11628219-B2
Application number	US-201816218457-A
Country	US
Kind code	B2
Filing date	Dec 12, 2018
Priority date	Aug 14, 2014
Publication date	Apr 18, 2023
Grant date	Apr 18, 2023

Abstract

This invention provides methods and systems for achieving high-specificity killing of targeted cells using Magneto-Electric Nano-Particles (MENPs) and functional or diagnostic imaging that detects changes at the cellular level. Embodiments comprise injecting into a patient's body manufactured MENPs that have a higher tendency to accumulate near or attach to targeted cells through one or more physical forces and/or biological mechanisms; and applying a magnetic field to the MENPs to generate an action that is sufficient to cause death of the targeted cells, and using an imaging apparatus to image or detect a specific property of the MENPs or changes in a property of the MENPs due to the coupling of the MENPs with their surrounding environment.

First claim

The invention claimed is:

1. A system for achieving high-specificity killing of targeted cells comprising:
Magneto-Electric Nano-Particles (MENPs), wherein the MENPs are not loaded with a drug intended to kill targeted cells,
an apparatus for injecting the MENPs into a patient's body, and
an apparatus for applying a magnetic field to the MENPs, to generate an electric field on the MENPs through their magneto-electric coupling property due to correlated magnetostrictive and piezoelectric effects of the MENPs;
wherein said apparatus for applying a magnetic field to the MENPs is an apparatus for applying a first magnetic field and a second magnetic field comprising a selector (or selecting module) to select the first magnetic field strength H with A<H<B where A and B are thresholds so that the MENPs achieve nano-electroporation to penetrate targeted cells but no or little nano-electroporation of non-targeted cells and to select the second magnetic field strength to induce the MENPs to generate one or more disruptive actions to disrupt the function of the targeted cells, including an electric gradient field, an alternating electric field, an alternating electric field at one or more ferromagnetic resonance frequency(ies) of the MENPs.

2. A method for targeted killing of targeted cells using the system of claim 1 , comprising
injecting the Magneto-Electric Nano-Particles (MENPs) into a patient's body wherein the MENPs are not loaded with a drug intended to kill targeted cells;
applying a first magnetic field at a level of H with A<H<B where A and B are thresholds so that the MENPs achieve nano-electroporation to penetrate targeted cells but no or little nano-electroporation of non-targeted cells; and
applying a second magnetic field to induce the MENPs to generate one or more disruptive actions to disrupt the function of the targeted cells, including an electric gradient field, an alternating electric field, an alternating electric field at one or more ferromagnetic resonance frequency(ies) of the MENPs.

3. The method of claim 2 , wherein the first magnetic field is applied prior to the application of the second magnetic field, or wherein the first magnetic field and the second magnetic field are applied concurrently.

4. The method of claim 2 , wherein a sufficiently long waiting period is inserted between the application of the first magnetic field and the second magnetic field to give the body sufficient time to move most or all of the free MENPs that did not penetrate or bind to targeted cells out of the body.

5. The method of claim 2 , wherein the strength and/or frequency of the second magnetic field is chosen to cause the MENPs that have penetrated into targeted cells to kill the targeted cells but does not cause other MENPs that still remain in the body to penetrate or harm untargeted cells.

6. The method of claim 2 , further comprising applying another magnetic field externally to produce higher concentration of MENPs at and around a localized targeted site or in an organ or body part, prior to the application of the first magnetic field.

7. The method of claim 6 , wherein a single apparatus is used to generate the first magnetic field, the second magnetic field and the third magnetic field.

8. The method of claim 2 , further comprising
using a sensor or imaging device to measure one or more of the following: the strength and/or gradient of the magnetic field at one or more location, the position and/or motion of the MENPs inside the body, or effective local electric field calculated from magnetic imaging of MENPs; and
using a feedback control loop that uses the measurement(s) to control the generation and application of the first and/or second magnetic field to achieve desired strength, frequency and/or distribution of the magnetic field.

9. The method of claim 2 , further comprising
using multiple permanent or electro-magnets arranged in an enclosure to generate a 3-dimensional magnetic field with sufficient strength in tissues or organ deep inside a human body by constructively superimposing magnetic field vectors from multiple magnets at targeted locations.

10. The method of claim 6 , further comprising
using a magnetic imaging device that produces measurements or images of the 3D distribution of the magnetic field; and
using the measurements or images to control the generation of the 3D magnetic field to guide MENPs to the desired location inside a human body and/or to generate magnetic field at a desired location to produce nano-electroporation of targeted cells and/or generate one or more of the disruptive actions.

11. The method of claim 10 , further comprising calibrating the magnetic imaging device to establish a sufficiently accurate mapping of the measurements or images of the 3D distribution of magnetic field to actual locations inside the patient's body.

Assignees

• Liang Ping

Inventors

• Liang Ping

Classifications

• A61N1/327

  for enhancing the absorption properties of tissue, e.g. by electroporation · CPC title

• A61K41/0052 Primary

  Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K49/1818

  particles, e.g. uncoated or non-functionalised microparticles or nanoparticles · CPC title

• A61K9/0009

  involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis · CPC title